Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis

BACKGROUND: In women with newly diagnosed ovarian cancer, bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) exhibit improved progression-free survival (PFS) when administered concurrent with chemotherapy and/or maintenance therapy, but no study has directly compared their effects. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Young Ju, Lee, Banghyun, Kim, Kidong, Jeong, Yujin, Choi, Hwa Yeon, Hwang, Sung Ook, Kim, Yong Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969379/
https://www.ncbi.nlm.nih.gov/pubmed/35354431
http://dx.doi.org/10.1186/s12885-022-09455-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969379/
https://www.ncbi.nlm.nih.gov/pubmed/35354431
http://dx.doi.org/10.1186/s12885-022-09455-x

Ejemplares similares